SAT-790 Vitamin D in Patients with Osteoporosis: a Retrospective Study from 2020 to 2024 at the Riga East University Hospital (REUH)

Abstract Disclosure: K. Berzina: None. I. Rasa: None. Introduction: . Osteoporosis is a global condition characterized by decreased bone density. Vitamin D plays a crucial role in bone formation and may benefit osteoporosis patients. Sufficient levels of vitamin D in the bloodstream are essential for the body to effectively absorb calcium, which is vital for maintaining good bone health and is associated with a reduced risk of fractures. Methods: . A retrospective study analyzed 505 unique osteoporosis patients from REUH, all treated in one medical centre. Data were collected from 2020 to 2024 and analyzed using IBM SPSS 29.0. Results: . Among 505 patients with an average age of 68.3±9.4 years, 90.3% (n=456) were female, 37.6% (n=190) of patients had experienced fractures, with 74.7% (n=142) of these fractures occurring before the initiation of osteoporosis treatment. Calcium supplements of 500 mg were taken by 82.4% (n=416) daily. Vitamin D by 89.3% (n=451). Vitamin D was given in doses from 1000IU daily to 50000IU weekly. Of all patients, 48.9% (n=247) have had bisphosphonates therapy, and 78% (n=384) have had denosumab in their lifetime. Vitamin D levels below 30.0±0.1ng/ml were seen in 18.6% (n=8) of patients who had fractures while on osteoporosis therapy, compared to 11.8% (n=40) of all other patients. Just 12.2% (n=53) of all patients had vitamin D levels lower than 30.0±0.1ng/ml, which decreased to 5.3% (n=24) following one year of appropriate and individualized supplementation. Patients who received 8000IU daily had the most significant average increase in vitamin D, with a 45% in one year for 32 patients. The most prescribed dose of vitamin D was 4000IU (n=101), an increase of 11.4% over a year. In contrast, lower doses ranging from 1000IU to 2000IU were less effective, showing gains of less than 0.6% or even decreases. Conclusions: . The research indicated that most patients with osteoporosis take calcium and vitamin D daily, with vitamin D administered in adequate amounts to ensure sufficient blood levels. Presentation: Saturday, July 12, 2025

Authors

Institutions

Publication Details

Journal
Journal of the Endocrine Society
Published
2025-10-01
DOI
https://doi.org/10.1210/jendso/bvaf149.643
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SAT-790 Vitamin D in Patients with Osteoporosis: a Retrospective Study from 2020 to 2024 at the Riga East University Hospital (REUH)

Ingvars Rasa, Katrina Elina Berzina
Journal of the Endocrine Society
Bone health and osteoporosis research
article

SAT-790 Vitamin D in Patients with Osteoporosis: a Retrospective Study from 2020 to 2024 at the Riga East University Hospital (REUH)

Ingvars Rasa, Katrina Elina Berzina
article en

Abstract

Abstract Disclosure: K. Berzina: None. I. Rasa: None. Introduction: . Osteoporosis is a global condition characterized by decreased bone density. Vitamin D plays a crucial role in bone formation and may benefit osteoporosis patients. Sufficient levels of vitamin D in the bloodstream are essential for the body to effectively absorb calcium, which is vital for maintaining good bone health and is associated with a reduced risk of fractures. Methods: . A retrospective study analyzed 505 unique osteoporosis patients from REUH, all treated in one medical centre. Data were collected from 2020 to 2024 and analyzed using IBM SPSS 29.0. Results: . Among 505 patients with an average age of 68.3±9.4 years, 90.3% (n=456) were female, 37.6% (n=190) of patients had experienced fractures, with 74.7% (n=142) of these fractures occurring before the initiation of osteoporosis treatment. Calcium supplements of 500 mg were taken by 82.4% (n=416) daily. Vitamin D by 89.3% (n=451). Vitamin D was given in doses from 1000IU daily to 50000IU weekly. Of all patients, 48.9% (n=247) have had bisphosphonates therapy, and 78% (n=384) have had denosumab in their lifetime. Vitamin D levels below 30.0±0.1ng/ml were seen in 18.6% (n=8) of patients who had fractures while on osteoporosis therapy, compared to 11.8% (n=40) of all other patients. Just 12.2% (n=53) of all patients had vitamin D levels lower than 30.0±0.1ng/ml, which decreased to 5.3% (n=24) following one year of appropriate and individualized supplementation. Patients who received 8000IU daily had the most significant average increase in vitamin D, with a 45% in one year for 32 patients. The most prescribed dose of vitamin D was 4000IU (n=101), an increase of 11.4% over a year. In contrast, lower doses ranging from 1000IU to 2000IU were less effective, showing gains of less than 0.6% or even decreases. Conclusions: . The research indicated that most patients with osteoporosis take calcium and vitamin D daily, with vitamin D administered in adequate amounts to ensure sufficient blood levels. Presentation: Saturday, July 12, 2025

Journal of the Endocrine SocietyVol. 9(Supplement_1)
Riga East University Hospital (LV), Riga Stradiņš University (LV), Bone Health and Osteoporosis Foundation (US)
Openalex Percentile: Top 61%
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.